Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

弥漫性大型B细胞淋巴瘤埃及患者中丙型肝炎病毒感染和治疗的独立预后因素

卷 20, 期 8, 2020

页: [638 - 645] 页: 8

弟呕挨: 10.2174/1568009620666200511084731

价格: $65

摘要

背景：埃及是最高的丙型肝炎病毒（HCV）流行地区之一。 慢性HCV感染具有肝外表现，包括非霍奇金淋巴瘤（NHL）。 弥漫性大B细胞淋巴瘤（DLBCL）通常与HCV感染相关。 迄今为止，HCV感染和HCV治疗对DLBCL患者的预后价值尚不清楚。 目的：我们的研究目的是评估HCV感染和HCV治疗作为独立预后因素对埃及HCV相关DLBCL患者无事件生存期（EFS）和总体生存期（OS）的影响。 方法：本研究回顾性收集了353例DLBCL患者。 前瞻性收集了34例接受HCV抗病毒治疗的HCV患者。 诊断时从患者记录中收集患者的特征。 还记录了有关HCV感染和HCV治疗的患者状况。 病历，复发，再治疗或死亡也通过医疗记录进行了验证。 计算了EFS和OS。 结果：与未感染HCV和HCV治疗的患者相比，HCV感染和HCV未治疗的患者的EFS和OS显着降低。 使用单变量和多变量分析，HCV感染而非HCV治疗与EFS和OS独立相关。 结论：丙型肝炎病毒感染是弥漫性大B细胞淋巴瘤EFS和OS的独立预后因素。 HCV治疗与较高的EFS和OS相关，但不能视为独立的预后因素。

关键词: 弥漫性大B细胞淋巴瘤，HCV，病毒性肝炎，生存，癌症，预后。

« Previous
图形摘要

[1]
Ghany, M.G.; Strader, D.B.; Thomas, D.L.; Seeff, L.B. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology, 2009, 49(4), 1335-1374.
[http://dx.doi.org/10.1002/hep.22759] [PMID: 19330875]
[2]
Gower, E.; Estes, C.; Blach, S.; Razavi-Shearer, K.; Razavi, H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol., 2014, 61(1)(Suppl.), S45-S57.
[http://dx.doi.org/10.1016/j.jhep.2014.07.027] [PMID: 25086286]
[3]
Waked, I.; Doss, W.; El-Sayed, M.H.; Estes, C.; Razavi, H.; Shiha, G.; Yosry, A.; Esmat, G. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J. Gastroenterol., 2014, 15(2), 45-52.
[http://dx.doi.org/10.1016/j.ajg.2014.04.003] [PMID: 25097045]
[4]
Ahmed, O.A.; Kaisar, H.H.; Badawi, R.; Hawash, N.; Samir, H.; Shabana, S.S.T.; Fouad, M.H.A.; Rizk, F.H.; Khodeir, S.A.; Abd-Elsalam, S. Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect. Drug Resist., 2018, 11, 295-298.
[http://dx.doi.org/10.2147/IDR.S153060] [PMID: 29535545]
[5]
Abdelmoemen, G.; Khodeir, S.A.; Abou-Saif, S.; Kobtan, A.; Abd-Elsalam, S. Prevalence of occult hepatitis C virus among hemodialysis patients in Tanta University Hospitals: A single-center study. Environ. Sci. Pollut. Res. Int., 2018, 25(6), 5459-5464.
[http://dx.doi.org/10.1007/s11356-017-0897-y] [PMID: 29214477]
[6]
Cacoub, P.; Poynard, T.; Ghillani, P.; Charlotte, F.; Olivi, M.; Piette, J.C.; Opolon, P. MULTIVIRC Group Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment virus C. Arthritis Rheum., 1999, 42(10), 2204-2212.
[http://dx.doi.org/10.1002/1529-0131(199910)42:10<2204:AID-ANR24>3.0.CO;2-D] [PMID: 10524695]
[7]
Dal Maso, L.; Franceschi, S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol. Biomarkers Prev., 2006, 15(11), 2078-2085.
[http://dx.doi.org/10.1158/1055-9965.EPI-06-0308] [PMID: 17119031]
[8]
Ennishi, D.; Maeda, Y.; Niitsu, N.; Kojima, M.; Izutsu, K.; Takizawa, J.; Kusumoto, S.; Okamoto, M.; Yokoyama, M.; Takamatsu, Y.; Sunami, K.; Miyata, A.; Murayama, K.; Sakai, A.; Matsumoto, M.; Shinagawa, K.; Takaki, A.; Matsuo, K.; Kinoshita, T.; Tanimoto, M. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: A Japanese multicenter analysis. Blood, 2010, 116(24), 5119-5125.
[http://dx.doi.org/10.1182/blood-2010-06-289231] [PMID: 20823454]
[9]
Cowgill, K.D.; Loffredo, C.A.; Eissa, S.A.; Mokhtar, N. Abdel-Hamid, M.; Fahmy, A.; Strickland, G.T. Case-control study of non-Hodgkin’ lymphoma and hepatitis C virus infection in Egypt. Int. J. Epidemiol., 2004, 33(5), 1034-1039.
[http://dx.doi.org/10.1093/ije/dyh183] [PMID: 15155696]
[10]
Youssef, S.S.; Nasr, A.S.; El Zanaty, T.; El Rawi, R.S.; Mattar, M.M. Prevalence of occult hepatitis C virus in egyptian patients with chronic lymphoproliferative disorders. Hepat. Res. Treat., 2012.2012429784
[http://dx.doi.org/10.1155/2012/429784] [PMID: 23304473]
[11]
Abu-Taleb, F.; El-Hefni, A.; Kotb, A.; El-Gohary, T.A. Efficacy of ribavirin to prevent hepatitis reactivation in hepatitis C virus infected patients treated for non-Hodgkin lymphoma. Afro-Egypt J. Infect. Endem. Dis., 2013, 3(1), 17-26.
[http://dx.doi.org/10.21608/aeji.2013.17092]
[12]
Hartridge-Lambert, S.K.; Stein, E.M.; Markowitz, A.J.; Portlock, C.S. Hepatitis C and non-Hodgkin lymphoma: The clinical perspective. Hepatology, 2012, 55(2), 634-641.
[http://dx.doi.org/10.1002/hep.25499] [PMID: 22120959]
[13]
Besson, C.; Canioni, D.; Lepage, E.; Pol, S.; Morel, P.; Lederlin, P. Groupe d’Etude des Lymphomes de l’Adulte Programs. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Grouped’Etude des Lymphomes de l’Adulte programs. J. Clin. Oncol., 2006, 24(6), 953-960.
[http://dx.doi.org/10.1200/JCO.2005.01.5016] [PMID: 16418500]
[14]
Visco, C.; Arcaini, L.; Brusamolino, E.; Burcheri, S.; Ambrosetti, A.; Merli, M.; Bonoldi, E.; Chilosi, M.; Viglio, A.; Lazzarino, M.; Pizzolo, G.; Rodeghiero, F. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: Analysis of 156 patients from northern Italy. Ann. Oncol., 2006, 17(9), 1434-1440.
[http://dx.doi.org/10.1093/annonc/mdl131] [PMID: 16766591]
[15]
Harris, N.L. Principles of the revised European–American lymphoma classification (from the International Lymphoma Study Group). Ann. Oncol., 1997, 8(Suppl. 2), 11-16.
[http://dx.doi.org/10.1093/annonc/8.suppl_2.S11] [PMID: 9209633]
[16]
Cheson, B.D.; Horning, S.J.; Coiffier, B.; Shipp, M.A.; Fisher, R.I.; Connors, J.M.; Lister, T.A.; Vose, J.; Grillo-López, A.; Hagenbeek, A.; Cabanillas, F.; Klippensten, D.; Hiddemann, W.; Castellino, R.; Harris, N.L.; Armitage, J.O.; Carter, W.; Hoppe, R.; Canellos, G.P. NCI Sponsored International Working Group Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J. Clin. Oncol., 1999, 17(4), 1244.
[http://dx.doi.org/10.1200/JCO.1999.17.4.1244] [PMID: 10561185]
[17]
Mohamed, A.A.; El-Toukhy, N.E.R.; Said, E.M.; Gabal, H.M.R.; AbdelAziz, H.; Doss, W.; El-Hanafi, H.; El Deeb, H.H.; Mahmoud, S.; Elkadeem, M.; Shalby, H.S.; Abd-Elsalam, S. Hepatitis C virus: Efficacy of new DAAs Regimens. Infect. Disord. Drug Targets, 2019.
[http://dx.doi.org/10.2174/1871526519666190121114003] [PMID: 30663575]
[18]
Park, B.B.; Kim, J.S.; Lee, Y.Y.; Kang, H.J.; Ryoo, B.Y.; Kang, J.H.; Kim, H.Y.; Kim, B.S.; Oh, S.Y.; Kwon, H.C.; Won, J.H.; Kim, K.; Park, K.; Suh, C.; Kim, W.S. Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. Leuk. Lymphoma, 2008, 49(1), 88-94.
[http://dx.doi.org/10.1080/10428190701732861] [PMID: 18203017]
[19]
Nishikawa, H.; Tsudo, M.; Osaki, Y. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: A single center experience. Oncol. Rep., 2012, 28(3), 835-840.
[http://dx.doi.org/10.3892/or.2012.1883] [PMID: 22736295]
[20]
Chen, Y.Y.; Huang, C.E.; Liang, F.W.; Lu, C.H.; Chen, P.T.; Lee, K.D.; Chen, C.C. Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index. Cancer Epidemiol., 2015, 39(3), 382-387.
[http://dx.doi.org/10.1016/j.canep.2015.04.004] [PMID: 25899771]
[21]
Dlouhy, I.; Torrente, M.Á.; Lens, S.; Rovira, J.; Magnano, L.; Giné, E.; Delgado, J.; Balagué, O.; Martínez, A.; Campo, E.; Forns, X.; Sánchez-Tapias, J.M.; López-Guillermo, A. Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Ann. Hematol., 2017, 96(3), 405-410.
[http://dx.doi.org/10.1007/s00277-016-2903-8] [PMID: 28035434]
[22]
Tsutsumi, Y.; Nakayama, C.; Kamada, K.; Kikuchi, R.; Kudo, D.; Ito, S.; Matsuoka, S.; Shiratori, S.; Yamamoto, Y.; Naruse, H.; Teshima, T. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma. Ann. Hematol., 2017, 96(12), 2057-2061.
[http://dx.doi.org/10.1007/s00277-017-3129-0] [PMID: 28939993]
[23]
Tsutsumi, Y.; Ito, S.; Ogasawara, R.; Kudo, K.; Tanaka, J.; Asaka, M.; Imamura, M. HCV virus and lymphoid neoplasms. Adv. Hematol., 2011.2011717951
[http://dx.doi.org/10.1155/2011/717951] [PMID: 21747860]
[24]
Hosry, J.; Mahale, P.; Turturro, F.; Miranda, R.N.; Economides, M.P.; Granwehr, B.P.; Torres, H.A. Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. Int. J. Cancer, 2016, 139(11), 2519-2528.
[http://dx.doi.org/10.1002/ijc.30372] [PMID: 27501007]
[25]
Chen, T.T.; Chiu, C.F.; Yang, T.Y.; Lin, C.C.; Sargeant, A.M.; Yeh, S.P.; Liao, Y.M.; Bai, L.Y. Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy. Leuk. Res., 2015b, 39(2), 151-156.
[http://dx.doi.org/10.1016/j.leukres.2014.11.015] [PMID: 25524176]
[26]
Arcaini, L.; Vallisa, D.; Rattotti, S.; Ferretti, V.V.; Ferreri, A.J.; Bernuzzi, P.; Merli, M.; Varettoni, M.; Chiappella, A.; Ambrosetti, A.; Tucci, A.; Rusconi, C.; Visco, C.; Spina, M.; Cabras, G.; Luminari, S.; Tucci, M.; Musto, P.; Ladetto, M.; Merli, F.; Stelitano, C.; d’Arco, A.; Rigacci, L.; Levis, A.; Rossi, D.; Spedini, P.; Mancuso, S.; Marino, D.; Bruno, R.; Baldini, L.; Pulsoni, A. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann. Oncol., 2014, 25(7), 1404-1410.
[http://dx.doi.org/10.1093/annonc/mdu166] [PMID: 24799461]
[27]
Merli, M.; Carli, G.; Arcaini, L.; Visco, C. Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. World J. Gastroenterol., 2016, 22(38), 8447-8458.
[http://dx.doi.org/10.3748/wjg.v22.i38.8447] [PMID: 27784957]
[28]
Hermine, O.; Lefrère, F.; Bronowicki, J.P.; Mariette, X.; Jondeau, K.; Eclache-Saudreau, V.; Delmas, B.; Valensi, F.; Cacoub, P.; Brechot, C.; Varet, B.; Troussard, X. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N. Engl. J. Med., 2002, 347(2), 89-94.
[http://dx.doi.org/10.1056/NEJMoa013376] [PMID: 12110736]
[29]
Sultanik, P.; Klotz, C.; Brault, P.; Pol, S.; Mallet, V. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood, 2015, 125(15), 2446-2447.
[http://dx.doi.org/10.1182/blood-2014-12-618652] [PMID: 25858892]
[30]
Economides, M.P.; Mahale, P.; Kyvernitakis, A.; Turturro, F.; Kantarjian, H.; Naing, A.; Hosry, J.; Shigle, T.L.; Kaseb, A.; Torres, H.A. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Aliment. Pharmacol. Ther., 2016, 44(11-12), 1235-1241.
[http://dx.doi.org/10.1111/apt.13825] [PMID: 27730654]
[31]
Torres, H.A.; Shigle, T.L.; Hammoudi, N.; Link, J.T.; Samaniego, F.; Kaseb, A.; Mallet, V. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J. Clin., 2017, 67(5), 411-431.
[http://dx.doi.org/10.3322/caac.21403] [PMID: 28683174]
[32]
Michot, J.M.; Canioni, D.; Driss, H.; Alric, L.; Cacoub, P.; Suarez, F.; Sibon, D.; Thieblemont, C.; Dupuis, J.; Terrier, B.; Feray, C.; Tilly, H.; Pol, S.; Leblond, V.; Settegrana, C.; Rabiega, P.; Barthe, Y.; Hendel-Chavez, H.; Nguyen-Khac, F.; Merle-Béral, H.; Berger, F.; Molina, T.; Charlotte, F.; Carrat, F.; Davi, F.; Hermine, O.; Besson, C. ANRS HC-13 Lympho-C Study Group. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am. J. Hematol., 2015, 90(3), 197-203.
[http://dx.doi.org/10.1002/ajh.23889] [PMID: 25417909]

Rights & Permissions Print Cite
Article Metrics
10
2
© 2024 Bentham Science Publishers | Privacy Policy